Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus
| Autor: | Hajime Baba, Ken Inada, Hitoshi Sakurai, Koichiro Watanabe, Ikuko Kishida, Masaki Kato, Toshiaki Kikuchi, Hiroyuki Uchida, Norio Yasui-Furukori, Yuka Sugawara Kikuchi, Asuka Katsuki, Takefumi Suzuki |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Olanzapine
medicine.medical_specialty Consensus medicine.medical_treatment Aripiprazole 03 medical and health sciences chemistry.chemical_compound Benzodiazepines Quetiapine Fumarate pharmacotherapy 0302 clinical medicine Extrapyramidal symptoms Japan medicine Humans Pharmacology (medical) Psychiatry Antipsychotic Brexpiprazole Original Paper Risperidone expert consensus business.industry General Medicine medicine.disease 030227 psychiatry schizophrenia Psychiatry and Mental health antipsychotics chemistry Schizophrenia Quetiapine medicine.symptom business 030217 neurology & neurosurgery medicine.drug Antipsychotic Agents |
| Zdroj: | Pharmacopsychiatry |
| ISSN: | 1439-0795 |
| Popis: | Introduction Conventional treatment guidelines of schizophrenia do not necessarily provide solutions on clinically important issues. Methods A total of 141 certified psychiatrists of the Japanese Society of Clinical Neuropsychopharmacology evaluated treatment options regarding 19 clinically relevant situations in the treatment of schizophrenia with a 9-point scale (1=“disagree” and 9=“agree”). Results First-line antipsychotics varied depending on predominant symptoms: risperidone (mean±standard deviation score, 7.9±1.4), olanzapine (7.5±1.6), and aripiprazole (6.9±1.9) were more likely selected for positive symptoms; aripiprazole (7.6±1.6) for negative symptoms; aripiprazole (7.3±1.9), olanzapine (7.2±1.9), and quetiapine (6.9±1.9) for depression and anxiety; and olanzapine (7.9±1.5) and risperidone (7.5±1.5) for excitement and aggression. While only aripiprazole was categorized as a first-line treatment for relapse prevention (7.6±1.0) in patients without noticeable symptoms, aripiprazole (8.0±1.6) and brexpiprazole (6.9±2.3) were categorized as such for social integration. First-line treatments in patients who are vulnerable to extrapyramidal symptoms include quetiapine (7.5±2.0) and aripiprazole (6.9±2.1). Discussion These clinical recommendations represent the expert consensus on the use of a particular antipsychotic medication for a particular situation, filling a current gap in the literature. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|